{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T10:44:39Z","timestamp":1694774679398},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"48","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Advanced non-small-cell lung cancer (NSCLC) is an aggressive malignancy that generally leads to poor outcomes, with &lt;5% long-term survival at 5 years; however, several researches have shown improvements in the progression-free survival (PFS) and overall survival (OS) on the maintenance therapy after the first-line chemotherapy. we report a case of metastatic NSCLC patient treated with maintenance therapy of gemcitabine with brilliant results.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>Clinical data and treatment of a 68-year-old man with NSCLC are summarized. The Ethics Committee of People's hospital of Leshan, approved this study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>Lung adenocarcinoma metastasized to the mediastinal lymph node, cervical lymph node, and adrenal gland, without epidermal growth factor receptor (EGFR) mutation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Continued treatment with gemcitabine alone following the 6 cycles of cisplatin\u2013gemcitabine chemotherapy, prolonging the interval of chemotherapy when he could not tolerate the toxicity of the drug.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Partial response of the disease for 4.5 years and significant clinical benefit.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>This case shows that patients will benefit from the maintenance therapy, and gemcitabine may be a good choice.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000013464","type":"journal-article","created":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T11:39:52Z","timestamp":1543491592000},"page":"e13464","source":"Crossref","is-referenced-by-count":2,"title":["Long-term clinical response of advanced lung adenocarcinoma to maintenance treatment of gemcitabine"],"prefix":"10.1097","volume":"97","author":[{"given":"Xingxing","family":"Lv","sequence":"first","affiliation":[{"name":"Department of Oncology and Hematology, People's Hospital of Leshan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fusheng","family":"Gou","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, People's Hospital of Leshan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, People's Hospital of Leshan, Leshan, Sichuan, PR China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, People's Hospital of Leshan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, People's Hospital of Leshan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, People's Hospital of Leshan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, People's Hospital of Leshan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, People's Hospital of Leshan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danfei","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, People's Hospital of Leshan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-24223-1_1","article-title":"Lung cancer statistics","volume":"893","author":"Torre","year":"2016","journal-title":"Adv Exp Med Biol"},{"issue":"(Suppl 17)","key":"R2-20230914","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1002\/cncr.29603","article-title":"Increased lung cancer mortality rates in the Chinese population from 1973-1975 to 2004-2005: An adverse health effect from exposure to smoking","volume":"121","author":"Zhi","year":"2015","journal-title":"Cancer"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.ejca.2012.11.021","article-title":"Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years","volume":"49","author":"Cufer","year":"2013","journal-title":"Eur J Cancer"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/cncr.24871","article-title":"Five-year lung cancer survival: which advanced stage nonsmall cell lung cancer patients attain long-term survival?","volume":"116","author":"Wang","year":"2010","journal-title":"Cancer"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/bmj.311.7010.899","article-title":"Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group","volume":"311","author":"Stewart","year":"1995","journal-title":"BMJ"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.lungcan.2011.12.011","article-title":"Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology","volume":"76","author":"Gridelli","year":"2012","journal-title":"Lung Cancer"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s11864-012-0209-1","article-title":"Advanced non-small cell lung cancer (NSCLC): maintenance therapy for all?","volume":"13","author":"Hashemi-Sadraei","year":"2012","journal-title":"Curr Treat Options Oncol"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/1758834011399306","article-title":"Maintenance therapy in advanced non-small cell lung cancer: evolution, tolerability and outcomes","volume":"3","author":"Coate","year":"2011","journal-title":"Ther Adv Med Oncol"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1200\/JCO.2012.47.9626","article-title":"PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer","volume":"31","author":"Patel","year":"2013","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1200\/JCO.2011.39.9782","article-title":"Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer","volume":"30","author":"Perol","year":"2012","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.lungcan.2006.01.006","article-title":"Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial","volume":"52","author":"Brodowicz","year":"2006","journal-title":"Lung Cancer"},{"key":"R14-20230914","first-page":"1043","article-title":"Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC)","author":"Belani","year":"1982","journal-title":"Asco Meeting"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(09)61497-5","article-title":"Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study","volume":"374","author":"Ciuleanu","year":"2009","journal-title":"Lancet"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S1470-2045(10)70112-1","article-title":"Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study","volume":"11","author":"Cappuzzo","year":"2010","journal-title":"Lancet Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201811300-00091","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T19:17:12Z","timestamp":1694719032000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201811300-00091"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":16,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000013464","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}